Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Pharmacological Postconditioning During the Aortic Valvular Surgery (PC Pharma CVA)

This study has been completed.
Information provided by (Responsible Party):
Hospices Civils de Lyon Identifier:
First received: September 29, 2009
Last updated: November 8, 2011
Last verified: November 2011
Primary objective: To evaluate the efficacy of the cyclosporin A administration to induce a cardioprotection during the valvular surgery.

Condition Intervention Phase
Aortic Valvular Surgery
Drug: cyclosporine A
Other: No injection
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind (Participant)
Primary Purpose: Treatment
Official Title: Pharmacological Postconditioning During the Aortic Valvular Surgery

Resource links provided by NLM:

Further study details as provided by Hospices Civils de Lyon:

Primary Outcome Measures:
  • The peak of the cardiac troponin I blood level measured during the first 72 hours of surgery follow-up. [ Time Frame: 72 hours ]

Secondary Outcome Measures:
  • Area under curve of the cardiac troponin I release, BNP, length of mechanical ventilation, length of stay in ICU, SAPS, necessity of a catecholaminergic support to assure hemodynamic stability, SAE [ Time Frame: 72 hours ]

Enrollment: 56
Study Start Date: October 2008
Study Completion Date: September 2010
Primary Completion Date: September 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: cyclosporine
a single bolus of 2.5 mg/kg, administered before aortic cross-declamping
Drug: cyclosporine A
a single bolus of 2.5 mg/kg, administered before aortic cross-declamping
No Intervention: Control
No cyclosporine A is administered before aortic cross-declamping
Other: No injection
No cyclosporine A is administered before aortic cross-declamping.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or females, scheduled for an aortic valvular surgery;
  • 18 years of age or older.

Exclusion Criteria:

  • Combined valvular and coronary surgery;
  • Significant coronary artery stenosis (upper than 70%);
  • Left ventricular dysfunction (ejection fraction < 40%);
  • Emergency surgery and/or infectious endocarditis;
  • Known cyclosporin hypersensitivity;
  • History of known recent immunosuppression (< 6 months): cancer, lymphoma, positive serology for HIV, hepatitis;
  • Renal insufficiency (creatininaemia > 150 µmol/l);
  • Hepatic insufficiency (prothrombin time < 50%);
  • Uncontrolled arterial hypertension defined by a systolic arterial pressure > 180 mm Hg;
  • Women of child bearing potential, who are pregnant or not under efficient contraception;
  • Patients treated with nicorandil, sulfonylurea or rosuvastatine;
  • Patients under judicial control.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00987207

Hôpital Louis Pradel
Lyon, France, 69394
Sponsors and Collaborators
Hospices Civils de Lyon
Principal Investigator: Pascal CHIARI, MD Hospices Civils de Lyon - France
  More Information

Responsible Party: Hospices Civils de Lyon Identifier: NCT00987207     History of Changes
Other Study ID Numbers: 2007.490
Study First Received: September 29, 2009
Last Updated: November 8, 2011

Keywords provided by Hospices Civils de Lyon:
cyclosporine A
myocardial ischemia
cardiac surgery
aortic valvulopathy

Additional relevant MeSH terms:
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antifungal Agents
Anti-Infective Agents
Dermatologic Agents
Antirheumatic Agents
Calcineurin Inhibitors processed this record on April 28, 2017